Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 1/20 | 0.61 |
| ▸ | MARS1 | P56192 | 6/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.57 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL923028 | 0.94 | RPA1 (0.68) | RPA1MARS1FAAHCHRNA7GABRA2 | |
| SCHEMBL342100 | 0.90 | MARS1 (0.68) | RPA1MARS1FAAHCHRNA7GABRA2 | |
| SCHEMBL29419099 | 0.90 | MARS1 (0.68) | RPA1MARS1FAAHCHRNA7GABRA2 | |
| SCHEMBL3816384 | 0.85 | MARS1 (0.57) | RPA1MARS1FAAHCHRNA7GABRA2 | |
| SCHEMBL4693715 | 0.84 | CHRNA7 (0.61) | RPA1MARS1FAAHCHRNA7GABRA2 | |
| SCHEMBL5797399 | 0.84 | GABRA2 (0.57) | FAAHCHRNA7GABRA2GABRB2MEN1 | |
| SCHEMBL29419139 | 0.84 | GABRA2 (0.59) | FAAHCHRNA7GABRA2GABRB2MEN1 | |
| SCHEMBL340947 | 0.84 | GABRA2 (0.59) | FAAHCHRNA7GABRA2GABRB2MEN1 | |
| SCHEMBL3818522 | 0.83 | CHRNA7 (0.54) | RPA1MARS1FAAHCHRNA7GABRA2 | |
| SCHEMBL2982610 | 0.82 | RPA1 (0.73) | RPA1MARS1GABRA2GABRB2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718617-B1 | 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | EP | disclosed |
| US-20090149463-A1 | Therapeutic agents | CHENG LEIFENG | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149463-A1 | Therapeutic agents | NLN, BDNF, GAP43 | RPA1 4861/4885MARS1 4373/4885FAAH 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.